arsenic trioxide induce apoptosis independent of tnfr-i and cd30 pathways in acute promyelocytic leukemia patient with t(15;17) translocation.

نویسندگان

ar ardjmand hematology oncology & b.m.t research center, tehran university of medical science, tehran, iran

k alimoghadam hematology oncology & b.m.t research center, tehran university of medical science, tehran, iran

s kaviani hematology dep., faculty of medicine, tarbiat modares university, tehran-iran

a ghavamzadeh hematology oncology & b.m.t research center, tehran university of medical science, tehran, iran

چکیده

arsenic trioxide (ato) has been reported to induce apoptosis in leukemic cells of acute promyelo-cytic leukemia (apl) patients through different pathways. however, the exact mechanism of ato-induced apoptosis is not yet clear. co stimulation of death receptors cd30 and tumor necrosis factor receptor type one (tnfr-i) is one of the postulated mechanisms.in the present study we aimed to evaluate their involvement in fresh promyelocytic cells separated from bone marrow of apl patients. immunomagnetic separated cells were treated up to 48 hr at clinically tolerable concentrations of ato (0.5-2.0 µmol/l) and expression of tnfr-i and cd30 were evaluated within the apoptotic and live populations using a sensitive triple color flow cytometric method for measuring apoptosis in combina tion with dual color immunofluorescence. our results suggest that the expression of tnfr-i and cd30 might not be related to  ato-induced apoptotic cell death.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide

It is well recognized that arsenic trioxide (ATO) is an efficacious agent for the treatment of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to remissions which are durable in the majority. ATO is probably the most effective single agent in the treatment of APL and there have been very few reports of primary resistance. It has been used both as a sing...

متن کامل

Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) has unique clinical, cytogenetic, and molecular features and is one of the most potentially curable human malignancies. The current standard treatment given to patients with newly diagnosed APL consists of all-trans retinoic acid and anthracycline-based cytotoxic chemotherapy, which is highly effective for remission induction. However, despite the potential fo...

متن کامل

A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia

Arsenic Trioxide is an old drug that has recently re- introduced into new medicine. It is very potent against a specific type of leukemic cells harboring translocation between chromosomes 15 and 17. It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia, including for remission induction of relapsed cases, or as first-line treatment. It is also u...

متن کامل

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

BACKGROUND All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsen...

متن کامل

a review of arsenic trioxide and acute promyelocytic leukemia.

arsenic trioxide is an old drug that has recently re- introduced into new medicine. it is very potent against a specific type of leukemic cells harboring translocation between chromosomes 15 and 17. it has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia, including for remission induction of relapsed cases, or as first-line treatment. it is also u...

متن کامل

Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report

UNLABELLED INTRODUCTION In the relapsed setting, arsenic trioxide remains the backbone of treatment. Scant literature exists regarding treatment of relapsed acute promyelocytic leukemia in patients with renal failure. To the best of our knowledge we are the first to report a safe and effective means of treatment for relapsed acute promyelocytic leukemia in the setting of advanced renal failu...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۲، شماره ۱، صفحات ۲۷-۳۱

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023